Perspective TherapeuticsCATX
About: Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Employees: 140
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
19,000% more call options, than puts
Call options by funds: $382K | Put options by funds: $2K
70% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 23
51% more capital invested
Capital invested by funds: $96.4M [Q1] → $146M (+$49.5M) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
4.06% less ownership
Funds ownership: 61.14% [Q1] → 57.08% (-4.06%) [Q2]
14% less funds holding
Funds holding: 112 [Q1] → 96 (-16) [Q2]
63% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 24
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
B. Riley Securities Yuan Zhi | 247%upside $12 | Buy Maintained | 23 Jun 2025 |
Wedbush David Nierengarten | 218%upside $11 | Outperform Reiterated | 23 Jun 2025 |
RBC Capital Leonid Timashev | 362%upside $16 | Outperform Maintained | 3 Jun 2025 |
Financial journalist opinion





![Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial](https://wsr-news.imgdelivr.io/pmQm6PP6.jpg?w=640&h=360)
![Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting](https://wsr-news.imgdelivr.io/BHYUo8HS.jpg?w=640&h=360)


